Analiese Michelle Hand, APRN
Family · Mandeville
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Analiese Michelle Hand’s office at (985) 951-4716 to ask if they take your plan before you enroll.
Medicaid work
$291,334 in 2024
Medicaid paid $291,334 for 3,444 billed services this clinician did in 2024, up to 147 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 1,831 | $291,334 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 37 | $0 |
| New patient visit (45+ min) | 16 | $0 |
| Short return visit (20+ min) | 928 | $0 |
| Return visit (30+ min) | 549 | $0 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 18-39 years | 19 | $0 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 40-64 years | 64 | $0 |
| 2024 | 3,444 | 7 | 147 | $291,334 |
| 2023 | 4,073 | 5 | 162 | $288,205 |
| 2022 | 3,597 | 6 | 143 | $245,868 |
| 2021 | 1,904 | 6 | 98 | $105,022 |
| 2020 | 337 | 4 | 78 | $14,644 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 2,220 | $288,205 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 30 | $0 |
| Short return visit (20+ min) | 1,722 | $0 |
| Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 18-39 years | 54 | $0 |
| Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 40-64 years | 47 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 1,883 | $245,868 |
| SARSCOV CORONAVIRUS AG IA | 15 | $0 |
| New patient visit (45+ min) | 91 | $0 |
| Short return visit (20+ min) | 1,432 | $0 |
| Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 18-39 years | 111 | $0 |
| Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 40-64 years | 65 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 940 | $96,294 |
| Return visit (30+ min) | 79 | $3,947 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 87 | $3,317 |
| New patient visit (30+ min) | 118 | $1,038 |
| Short return visit (20+ min) | 527 | $426 |
| New patient visit (45+ min) | 153 | $0 |
2020
| Return visit (30+ min) | 115 | $5,895 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 159 | $5,848 |
| New patient visit (30+ min) | 50 | $2,518 |
| Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, amplified probe technique | 13 | $382 |
Drugs they prescribed that Part D paid
$233,014
Pharmacies billed $233,014 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,243 generic and fewer than 11 brand-name prescriptions · $233,014 in drug cost · 28 antibiotic prescriptions to 20 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 47 | $50,717 | $1,079 |
| Jardiance | 68 | $48,724 | $717 |
| Mounjaro | 28 | $31,098 | $1,111 |
| Trelegy Ellipta | 37 | $24,259 | $656 |
| Myrbetriq | 14 | $6,419 | $459 |
See all 37 drugs
| Ozempic | 47 | $50,717 | $1,079 |
| Jardiance | 68 | $48,724 | $717 |
| Mounjaro | 28 | $31,098 | $1,111 |
| Trelegy Ellipta | 37 | $24,259 | $656 |
| Myrbetriq | 14 | $6,419 | $459 |
| Repatha | 11 | $6,082 | $553 |
| Vascepa | 13 | $4,661 | $359 |
| Janumet Xr | 12 | $3,464 | $289 |
| Albuterol Sulfate Hfa | 67 | $1,610 | $24 |
| Atorvastatin | 136 | $606 | $4 |
| Gabapentin | 62 | $471 | $8 |
| Lisinopril | 103 | $382 | $4 |
| Testosterone Cypionate | 17 | $377 | $22 |
| Metformin | 76 | $329 | $4 |
| Diclofenac | 15 | $295 | $20 |
| Amlodipine Besylate | 89 | $289 | $3 |
| Desloratadine | 11 | $280 | $25 |
| Metoprolol | 37 | $265 | $7 |
| Omeprazole | 23 | $242 | $11 |
| Rosuvastatin | 30 | $180 | $6 |
| Losartan-Hydrochlorothiazide | 23 | $177 | $8 |
| Nifedipine Er | 16 | $175 | $11 |
| Losartan | 33 | $167 | $5 |
| Famotidine | 14 | $153 | $11 |
| Hydrochlorothiazide | 64 | $146 | $2 |
| Methylprednisolone | 12 | $138 | $11 |
| Potassium Chloride | 21 | $134 | $6 |
| Fluticasone Propionate | 12 | $128 | $11 |
| Clonidine | 20 | $108 | $5 |
| Buspirone | 14 | $95 | $7 |
| Pantoprazole | 24 | $92 | $4 |
| Levothyroxine | 35 | $67 | $2 |
| Spironolactone | 17 | $59 | $3 |
| Trazodone | 17 | $58 | $3 |
| Carvedilol | 16 | $53 | $3 |
| Fenofibrate | 13 | $44 | $3 |
| Montelukast | 11 | $37 | $3 |
Year by year
| 2024 | 1,571 | 66 | None | None | $233,014 |
| 2023 | 1,219 | 58 | None | 14% | $117,659 |
| 2022 | 702 | 46 | None | None | $38,264 |
| 2021 | 300 | 78 | 0% (0) | None | $24,779 |
| 2020 | 456 | 307 | None | None | $8,615 |
| 2019 | 264 | 165 | None | 14% | $4,679 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 25 drugs
| Ozempic | 29 | $31,653 | $1,091 |
| Jardiance | 18 | $19,147 | $1,064 |
| Myrbetriq | 15 | $7,331 | $489 |
| Symbicort | 12 | $5,013 | $418 |
| Albuterol Sulfate Hfa | 58 | $2,073 | $36 |
| Atorvastatin | 139 | $1,329 | $10 |
| Gabapentin | 68 | $1,054 | $15 |
| Lisinopril | 92 | $771 | $8 |
| Metformin | 60 | $699 | $12 |
| Amlodipine Besylate | 91 | $492 | $5 |
| Testosterone Cypionate | 22 | $448 | $20 |
| Diclofenac | 20 | $397 | $20 |
| Losartan | 32 | $356 | $11 |
| Losartan-Hydrochlorothiazide | 16 | $349 | $22 |
| Propranolol | 18 | $338 | $19 |
| Levothyroxine | 26 | $248 | $10 |
| Omeprazole | 31 | $206 | $7 |
| Metoprolol | 17 | $186 | $11 |
| Fluticasone Propionate | 16 | $174 | $11 |
| Ibu | 45 | $159 | $4 |
| Pantoprazole | 19 | $157 | $8 |
| Clonidine | 23 | $108 | $5 |
| Ropinirole | 15 | $102 | $7 |
| Cyclobenzaprine | 17 | $79 | $5 |
| Hydrochlorothiazide | 16 | $41 | $3 |
2022: 18 drugs
| Myrbetriq | 17 | $7,963 | $468 |
| Atorvastatin | 73 | $747 | $10 |
| Albuterol Sulfate Hfa | 19 | $703 | $37 |
| Ventolin Hfa | 11 | $689 | $63 |
| Lisinopril | 61 | $503 | $8 |
| Amlodipine Besylate | 74 | $393 | $5 |
| Metformin | 35 | $321 | $9 |
| Potassium Chloride | 13 | $295 | $23 |
| Tamsulosin | 12 | $291 | $24 |
| Gabapentin | 25 | $245 | $10 |
| Levothyroxine | 19 | $241 | $13 |
| Benztropine Mesylate | 12 | $187 | $16 |
| Fluticasone Propionate | 14 | $170 | $12 |
| Metoprolol | 19 | $144 | $8 |
| Pantoprazole | 20 | $136 | $7 |
| Losartan | 13 | $105 | $8 |
| Omeprazole | 17 | $84 | $5 |
| Carvedilol | 12 | $75 | $6 |
2021: 6 drugs
| Levothyroxine | 16 | $205 | $13 |
| Atorvastatin | 14 | $199 | $14 |
| Tamsulosin | 11 | $165 | $15 |
| Gabapentin | 14 | $121 | $9 |
| Amlodipine Besylate | 19 | $102 | $5 |
| Lisinopril | 11 | $83 | $8 |
2020: 13 drugs
| Albuterol Sulfate Hfa | 33 | $1,460 | $44 |
| Azelastine | 41 | $1,197 | $29 |
| Doxycycline Hyclate | 27 | $516 | $19 |
| Nitrofurantoin Mono-Macro | 30 | $478 | $16 |
| Amoxicillin-Clavulanate Potass | 37 | $431 | $12 |
| Fluticasone Propionate | 27 | $267 | $10 |
| Mupirocin | 37 | $260 | $7 |
| Ondansetron Odt | 11 | $171 | $16 |
| Prednisone | 45 | $169 | $4 |
| Cephalexin | 20 | $131 | $7 |
| Azithromycin | 14 | $85 | $6 |
| Ciprofloxacin | 11 | $62 | $6 |
| Naproxen | 15 | $55 | $4 |
2019: 9 drugs
| Ventolin Hfa | 15 | $870 | $58 |
| Albuterol Sulfate Hfa | 11 | $528 | $48 |
| Doxycycline Hyclate | 21 | $356 | $17 |
| Amoxicillin-Clavulanate Potass | 27 | $290 | $11 |
| Fluticasone Propionate | 18 | $235 | $13 |
| Mupirocin | 15 | $179 | $12 |
| Nitrofurantoin Mono-Macro | 11 | $148 | $13 |
| Azithromycin | 19 | $140 | $7 |
| Prednisone | 30 | $82 | $3 |
Money from drug and device companies
$1,929 in 2025
| 2025 | 19 | 94 | None | $1,929 |
| 2024 | 21 | 75 | None | $1,563 |
| 2023 | 8 | 39 | None | $687 |
| 2022 | 9 | 29 | None | $504 |
| 2021 | 8 | 29 | None | $501 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Axsome Therapeutics | Auvelity | $354 | 16 payments
|
| Abbvie | Vraylar | $231 | 16 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $218 | 16 payments
|
| Astellas Pharma US | Veozah | $189 | 4 payments
|
| ViiV Healthcare | Dovato | $151 | 3 payments
|
| Teva Pharmaceuticals USA | Uzedy | $149 | 8 payments
|
See all 94 published payments
| Axsome Therapeutics | Meals · 2025-12-11 | Auvelity | $14 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-12-10 | Caplyta | $5 |
| Vanda Pharmaceuticals | Meals · 2025-12-09 | Fanapt | $14 |
| Alkermes | Meals · 2025-12-08 | Vivitrol | $25 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-12-03 | Caplyta | $14 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-11-21 | Caplyta | $14 |
| Axsome Therapeutics | Meals · 2025-11-20 | Auvelity | $14 |
| Alkermes | Meals · 2025-11-19 | Vivitrol | $16 |
| Exact Sciences | Meals · 2025-11-17 | The Cologuard Plus Collection Kit | $14 |
| Lundbeck | Meals · 2025-11-14 | Rexulti | $15 |
| Vanda Pharmaceuticals | Meals · 2025-11-13 | Fanapt | $23 |
| Teva Pharmaceuticals USA | Meals · 2025-11-12 | Uzedy | $10 |
| Abbvie | Meals · 2025-11-11 | Vraylar | $10 |
| Axsome Therapeutics | Meals · 2025-11-10 | Auvelity | $15 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-11-07 | Caplyta | $4 |
| Abbvie | Meals · 2025-11-04 | Vraylar | $12 |
| Axsome Therapeutics | Meals · 2025-10-23 | Auvelity | $15 |
| Abbvie | Meals · 2025-10-21 | Vraylar | $13 |
| Otsuka America Pharmaceutical | Meals · 2025-10-15 | Abilify Asimtufii | $17 |
| Vanda Pharmaceuticals | Meals · 2025-10-15 | Fanapt | $25 |
| Axsome Therapeutics | Meals · 2025-10-15 | Auvelity | $9 |
| Alkermes | Meals · 2025-10-14 | Aristada | $19 |
| ViiV Healthcare | Meals · 2025-10-08 | Dovato | $125 |
| Teva Pharmaceuticals USA | Meals · 2025-10-06 | Uzedy | $21 |
| Noven Therapeutics | Meals · 2025-10-03 | Xelstrym | $14 |
| Abbvie | Meals · 2025-09-30 | Vraylar | $11 |
| Gilead Sciences | Meals · 2025-09-30 | None | $31 |
| Astellas Pharma US | Education · 2025-09-30 | None | $100 |
| ViiV Healthcare | Meals · 2025-09-19 | Dovato | $5 |
| Astellas Pharma US | Meals · 2025-09-12 | Veozah | $35 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-09-09 | Caplyta | $18 |
| Vanda Pharmaceuticals | Meals · 2025-09-02 | Fanapt | $25 |
| Janssen Pharmaceuticals | Meals · 2025-08-27 | Spravato | $24 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-08-27 | Caplyta | $17 |
| GlaxoSmithKline | Meals · 2025-08-26 | Trelegy Ellipta | $16 |
| Gilead Sciences | Meals · 2025-08-25 | None | $31 |
| Teva Pharmaceuticals USA | Meals · 2025-08-20 | Uzedy | $17 |
| Abbvie | Meals · 2025-08-19 | Vraylar | $15 |
| Janssen Pharmaceuticals | Meals · 2025-08-18 | Invega Sustenna | $19 |
| ViiV Healthcare | Meals · 2025-08-18 | Dovato | $21 |
| Axsome Therapeutics | Meals · 2025-08-12 | Auvelity | $19 |
| Teva Pharmaceuticals USA | Meals · 2025-08-08 | Austedo Xr | $19 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-08-06 | Caplyta | $15 |
| Supernus Pharmaceuticals | Meals · 2025-08-01 | Qelbree | $25 |
| Abbvie | Meals · 2025-07-30 | Vraylar | $29 |
| Astellas Pharma US | Meals · 2025-07-27 | Veozah | $33 |
| Abbvie | Meals · 2025-07-22 | Vraylar | $23 |
| Lundbeck | Meals · 2025-07-21 | Rexulti | $16 |
| Axsome Therapeutics | Meals · 2025-07-16 | Auvelity | $19 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-07-16 | Caplyta | $9 |
| Exact Sciences | Meals · 2025-07-15 | The Cologuard Plus Collection Kit | $14 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-07-09 | Caplyta | $13 |
| Abbvie | Meals · 2025-06-25 | Vraylar | $16 |
| Alkermes | Meals · 2025-06-24 | Aristada | $22 |
| Axsome Therapeutics | Meals · 2025-06-24 | Auvelity | $25 |
| Axsome Therapeutics | Meals · 2025-06-04 | Auvelity | $115 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-06-04 | Caplyta | $7 |
| Abbvie | Meals · 2025-06-03 | Vraylar | $15 |
| Axsome Therapeutics | Meals · 2025-05-29 | Auvelity | $17 |
| Neurocrine BioSciences | Meals · 2025-05-28 | Ingrezza | $14 |
| Alkermes | Meals · 2025-05-27 | Aristada | $23 |
| Abbvie | Meals · 2025-05-21 | Vraylar | $18 |
| Astellas Pharma US | Meals · 2025-05-16 | Veozah | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-15 | Cobenfy | $43 |
| Abbvie | Meals · 2025-05-13 | Vraylar | $15 |
| Neurocrine BioSciences | Meals · 2025-05-09 | Ingrezza | $31 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-05-08 | Caplyta | $16 |
| Abbvie | Meals · 2025-05-06 | Vraylar | $10 |
| Lundbeck | Meals · 2025-05-06 | Rexulti | $18 |
| Alkermes | Meals · 2025-04-25 | Aristada | $12 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-04-25 | Caplyta | $13 |
| Axsome Therapeutics | Meals · 2025-04-24 | Auvelity | $24 |
| Teva Pharmaceuticals USA | Meals · 2025-04-16 | Austedo Xr | $23 |
| Exact Sciences | Meals · 2025-04-09 | Cologuard Collection Kit | $23 |
| Axsome Therapeutics | Meals · 2025-04-03 | Auvelity | $20 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-04-03 | Caplyta | $23 |
| Teva Pharmaceuticals USA | Meals · 2025-03-27 | Uzedy | $18 |
| Abbvie | Meals · 2025-03-25 | Vraylar | $9 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-03-24 | Xifaxan | $17 |
| Abbvie | Meals · 2025-03-19 | Vraylar | $10 |
| Axsome Therapeutics | Meals · 2025-03-18 | Auvelity | $14 |
| Axsome Therapeutics | Meals · 2025-03-13 | Auvelity | $11 |
| Teva Pharmaceuticals USA | Meals · 2025-03-13 | Austedo Xr | $13 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-03-11 | Caplyta | $17 |
| Neurocrine BioSciences | Meals · 2025-03-05 | Ingrezza | $15 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-02-28 | Caplyta | $13 |
| Lundbeck | Meals · 2025-02-23 | Rexulti | $18 |
| Axsome Therapeutics | Meals · 2025-01-30 | Auvelity | $15 |
| Alkermes | Meals · 2025-01-16 | Aristada | $23 |
| Axsome Therapeutics | Meals · 2025-01-16 | Auvelity | $9 |
| Abbvie | Meals · 2025-01-15 | Vraylar | $11 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-01-14 | Caplyta | $19 |
| Abbvie | Meals · 2025-01-10 | Vraylar | $14 |
| Teva Pharmaceuticals USA | Meals · 2025-01-07 | Uzedy | $27 |
See earlier years (2024, 2023, 2022, 2021)
2024: $1,563
| Axsome Therapeutics | Auvelity | $244 | 7 payments
|
| Abbvie | Vraylar | $201 | 13 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $191 | 11 payments
|
| Abbott Laboratories | Freestyle Libre | $156 | 2 payments
|
| Lundbeck | Rexulti | $149 | 8 payments
|
| Neurocrine Biosciences | Ingrezza | $141 | 7 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $74 | 4 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $62 | 4 payments
|
| Otsuka America Pharmaceutical | Rexulti | $51 | 3 payments
|
| Gilead Sciences | None | $46 | 2 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $45 | 2 payments
|
| Indivior | Sublocade | $34 | 2 payments
|
| Amgen | Otezla | $30 | 2 payments
|
| Tris Pharma | Dyanavel Xr | $21 | 1 payment
|
| Janssen Pharmaceuticals | Spravato | $20 | 1 payment
|
| Exact Sciences | Cologuard Collection Kit | $18 | 1 payment
|
| Phadia US | Immunocap | $17 | 1 payment
|
| Lilly USA | Mounjaro | $17 | 1 payment
|
| Merck Sharp & Dohme | Pifeltro | $17 | 1 payment
|
| Alkermes | Vivitrol | $15 | 1 payment
|
| Astellas Pharma US | Veozah | $15 | 1 payment
|
2023: $687
| Abbvie | Vraylar | $345 | 19 payments
|
| Iti | Caplyta | $129 | 8 payments
|
| Lundbeck | Rexulti | $56 | 4 payments
|
| Alkermes | Vivitrol | $43 | 2 payments
|
| Otsuka America Pharmaceutical | Abilify Asimtufii | $39 | 2 payments
|
| Lilly USA | Mounjaro | $30 | 2 payments
|
| Gilead Sciences | None | $29 | 1 payment
|
| Teva Pharmaceuticals USA | Austedo | $15 | 1 payment
|
2022: $504
| Iti | Caplyta | $185 | 10 payments
|
| Teva Pharmaceuticals USA | Austedo | $95 | 6 payments
|
| Alkermes | Aristada | $78 | 4 payments
|
| Lundbeck | Rexulti | $50 | 3 payments
|
| Neurocrine Biosciences | Ingrezza | $32 | 2 payments
|
| Otsuka America Pharmaceutical | Abilify Maintena | $18 | 1 payment
|
| Phadia US | Immunocap | $16 | 1 payment
|
| Gilead Sciences | None | $15 | 1 payment
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $15 | 1 payment
|
2021: $501
| Otsuka America Pharmaceutical | Rexulti | $127 | 6 payments
|
| Alkermes | Aristada | $116 | 7 payments
|
| Lundbeck | Rexulti | $83 | 5 payments
|
| Iti | Caplyta | $62 | 4 payments
|
| Gilead Sciences | None | $61 | 3 payments
|
| Teva Pharmaceuticals USA | Austedo | $26 | 2 payments
|
| Lilly USA | Emgality | $15 | 1 payment
|
| AbbVie | Vraylar | $11 | 1 payment
|
Professional record
- NPI
- 1043877509
- Licence
- LA 204307
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 160 Dunleith Ln, Mandeville, LA, 70471
- NPI first listed
- 2019-05-21
- NPI last updated
- 2022-02-03
- NPI record certified
- 2022-01-27
This is when the NPI record was last certified, not a medical board exam.